Group 1: Talent Development and Management - The company emphasizes continuous innovation in recruitment and talent management to align with strategic goals [2][3] - Plans to enhance employee training through the establishment of a dedicated training institution and collaboration with external consulting firms [3] Group 2: Shareholder Returns - For 2024, the company plans to distribute cash dividends of RMB 3 per 10 shares, totaling RMB 30.84 million [4] - Additionally, the company will increase its share capital by 3 shares for every 10 shares held, resulting in an increase of 3,084,000 shares [4] Group 3: Future Development Plans - The company aims to deepen its focus on fine chemicals, particularly in the pharmaceutical sector, while pursuing technological research and industrial exploration [5] - It seeks to become a trusted leader in the industry by aligning with the new development pattern of domestic and international dual circulation [5] Group 4: Market and Product Development - The company is committed to high-end and fine development strategies in the iodide product sector, enhancing R&D investment and market expansion [8] - It aims to optimize market layout and improve brand influence to achieve high-quality growth in iodide products [8] Group 5: Financial Performance - In 2024, the company achieved a revenue of RMB 132.79 million, representing a year-on-year growth of 29.53% [11] - The net profit attributable to shareholders was RMB 21.31 million, reflecting a year-on-year increase of 17.04% [11]
博苑股份(301617) - 2025年5月13日投资者关系活动记录表